Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
– Topline data expected in 4Q24 could support sNDA filing in 1H25 – – Revumenib has the potential to address $2 billion mNPM1 and KMT2Ar R/R acute leukemia U.S. market opportunity – WALTHAM, M
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
04:05pm, Tuesday, 26'th Mar 2024
– PDUFA action date set for September 26, 2024 – – NDA being reviewed under FDA's RTOR program – WALTHAM, Mass., March 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinica
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
07:00am, Monday, 18'th Mar 2024
– Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax – – Company on track for two potential first- and best-in-class product launches i
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Mar 2024
WALTHAM, Mass. , March 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript
09:21pm, Tuesday, 27'th Feb 2024
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
04:05pm, Tuesday, 27'th Feb 2024
– BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 – – NDA for revumenib in R/R KMT2Ar acute leukemia submitted under FDA's RTOR prog
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Monday, 26'th Feb 2024
Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sho
Syndax Announces Participation at Two Upcoming Investor Conferences
07:00am, Monday, 26'th Feb 2024
WALTHAM, Mass. , Feb. 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
04:05pm, Tuesday, 20'th Feb 2024
WALTHAM, Mass. , Feb. 20, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd Feb 2024
WALTHAM, Mass. , Feb. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript
09:26pm, Thursday, 02'nd Nov 2023
Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript
Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
02:52pm, Friday, 13'th Oct 2023
Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remis
Syndax Pharmaceuticals fall despite positive leukemia
09:22am, Monday, 02'nd Oct 2023
Syndax Pharmaceuticals (NASDAQ:SNDX) Inc (Syndax Pharmaceuticals (NASDAQ:SNDX)) stock was on the back foot on Monday, after reporting results from a leukaemia drug trial which met its primary endpoint
SmileDirectClub shares plunge after bankruptcy filing, with Syndax and AMC shares climbing and other active stocks
05:41am, Monday, 02'nd Oct 2023
Syndax Pharmaceuticals Inc. SNDX, -7.10% rose 19% in premarket trading. The clinical stage biopharmaceutical company said late Friday that it would release topline results from its trial of Revumenib
WALTHAM, Mass. , Sept. 29, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
